NantHealth Announces Research Results that Advances Understanding of Tumor Treatment Resistance
June 25 2020 - 8:00AM
Business Wire
Study Published in JCI Insight sheds light on
the importance of using both transcriptomics and genomics for
patient tumor interrogation to gain actionable insight
NantHealth, Inc. (NASDAQ: NH), a next-generation,
evidence-based, personalized healthcare company, today announced
the publication of a study in JCI Insight, a peer-reviewed journal
dedicated to biomedical research from preclinical to clinical
studies. This research looked into the discordance between genomic
sequencing and transcriptome analysis, and how this may reflect a
mechanism of resistance to therapy in tumors that has previously
been under-recognized and should be subject to further
investigation.
Next-generation sequencing (NGS) of DNA has not revealed all the
mechanisms underlying resistance to genomically matched drugs. This
study was designed to discover another potential mechanism.
Researchers evaluated data from 1,417 tumors whole-exome tumor
(somatic)/normal (germline) NGS and whole-transcriptome sequencing
in order to examine transcriptomic silencing of putative driver
alterations. Drivers are significant in this context, compared to
passenger mutations, which are not linked to targeted drug
therapies. Thus the data is particularly clinically relevant
because it pertains to mutations that are commonly used to
prescribe drug therapies. In this large-scale study, they also
determined the frequency of tumor mutations being germline, rather
than somatic, in these and an additional 462 tumors with tumor and
normal exomes. They found there was a high risk of germline
mutations being falsely reported as somatic. In that event,
clinicians may prescribe a treatment that would actually target the
normal healthy germline cells in addition to tumor cells and result
in greater toxicity. In examination of a set of 50 genes highly
associated with cancer and targeted therapies, at least 13% of
variants detected in DNA were unexpectedly not expressed.
The research confirmed that both the frequency of silenced
variant transcription and the risk of falsely identifying germline
mutations as somatic are important. Therefore, transcriptomics is
critical in conjunction with genomics when interrogating patient
tumors for actionable alterations, and to ultimately reduce the
risk of therapeutic resistance.
“Exploring another mechanism of resistance to therapy and thus
helping bring about a deeper understanding around the interrogation
of patients’ tumors brings with it hope and excitement for the
success of future therapeutics,” said Dr. Sandeep “Bobby” Reddy,
Chief Medical Officer, NantHealth. “NantHealth is dedicated to the
fight against cancer, devoting much time to finding effective
personalized cancer treatments. The recognition of transcriptomic
silencing means that we may be giving targeted therapies to up to
13% of patients in whom the target is actually missing.”
JCI Insight publishes well-executed, high-quality, insightful
research in all biomedical specialties, including autoimmunity,
gastroenterology, immunology, metabolism, nephrology, neuroscience,
oncology, pulmonology, vascular biology and many others. JCI
Insight builds on the editorial leadership of the JCI, one of the
oldest and most respected biomedical research journals, and is
self-published by the American Society for Clinical Investigation
(ASCI). JCI Insight serves to fulfill the ASCI’s objective to
advance medical science through the publication of clinically
relevant research reports.
NantHealth is focused on using data to close the loop –
connecting payers, providers, and patients. Through its software,
it facilitates the delivery of precise and timely data for creating
efficiency, personalized treatment, and collaboration across
healthcare.
About NantHealth, Inc.
NantHealth, a member of the NantWorks ecosystem of companies,
provides leading solutions across the continuum of care for
physicians, payers, patients and biopharmaceutical organizations.
NantHealth enables the use of cutting-edge data and technology
toward the goals of empowering clinical decision support and
improving patient outcomes. NantHealth’s comprehensive product
portfolio combines the latest technology in payer/provider
platforms that exchange information in near-real time (NaviNet and
Eviti), and molecular profiling services that combine comprehensive
DNA & RNA tumor-normal profiling with pharmacogenomics analysis
(GPS Cancer®). For more information, please visit nanthealth.com or
follow us on Twitter, Facebook and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200625005286/en/
NANT Jen Hodson Jen@nant.com 562-397-3639
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Aug 2024 to Sep 2024
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Sep 2023 to Sep 2024